Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer
Marie Wong,Chelsea Mayoh,Loretta M. S. Lau,Dong-Anh Khuong-Quang,Mark Pinese,Amit Kumar,Paulette Barahona,Emilie E. Wilkie,Patricia Sullivan,Rachel Bowen-James,Mustafa Syed,Iñigo Martincorena,Federico Abascal,Alexandra Sherstyuk,Noemi A. Bolanos,Jonathan Baber,Peter Priestley,M. Emmy M. Dolman,Emmy D. G. Fleuren,Marie-Emilie Gauthier,Emily V. A. Mould,Velimir Gayevskiy,Andrew J. Gifford,Dylan Grebert-Wade,Patrick A. Strong,Elodie Manouvrier,Meera Warby,David M. Thomas,Judy Kirk,Katherine Tucker,Tracey O’Brien,Frank Alvaro,Geoffry B. McCowage,Luciano Dalla-Pozza,Nicholas G. Gottardo,Heather Tapp,Paul Wood,Seong-Lin Khaw,Jordan R. Hansford,Andrew S. Moore,Murray D. Norris,Toby N. Trahair,Richard B. Lock,Vanessa Tyrrell,Michelle Haber,Glenn M. Marshall,David S. Ziegler,Paul G. Ekert,Mark J. Cowley
DOI: https://doi.org/10.1038/s41591-020-1072-4
IF: 82.9
2020-10-05
Nature Medicine
Abstract:The Zero Childhood Cancer Program is a precision medicine program to benefit children with poor-outcome, rare, relapsed or refractory cancer. Using tumor and germline whole genome sequencing (WGS) and RNA sequencing (RNAseq) across 252 tumors from high-risk pediatric patients with cancer, we identified 968 reportable molecular aberrations (39.9% in WGS and RNAseq, 35.1% in WGS only and 25.0% in RNAseq only). Of these patients, 93.7% had at least one germline or somatic aberration, 71.4% had therapeutic targets and 5.2% had a change in diagnosis. WGS identified pathogenic cancer-predisposing variants in 16.2% of patients. In 76 central nervous system tumors, methylome analysis confirmed diagnosis in 71.1% of patients and contributed to a change of diagnosis in two patients (2.6%). To date, 43 patients have received a recommended therapy, 38 of whom could be evaluated, with 31% showing objective evidence of clinical benefit. Comprehensive molecular profiling resolved the molecular basis of virtually all high-risk cancers, leading to clinical benefit in some patients.
biochemistry & molecular biology,cell biology,medicine, research & experimental